112 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs … internally or in collaboration with a partner. To accomplish this, we continue to supplement our research and development activities with our
6-K
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
Therapeutics for Acute Respiratory Distress Syndrome (ARDS)”. The Company announced that Biomedical Advanced Research and Development Authority (BARDA
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health … and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development
6-K
EX-99.1
jkkxfy
21 May 24
Report of Foreign Private Issuer
4:15pm
6-K
EX-99.1
xtu2mkpv
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.2
a4hir
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.3
xwch5ciwl39odeb56hz
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
5qwub8hyz3gq2
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
bi8 767q5yj3gar
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
cod7m cep
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
fexm reyd8
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
gjy 9y2fc4x
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
btu6hbnog5gki4r1xb4
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.1
mscitgg3
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.2
dl06uvmpsy9kmt3
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
lzt4y00s ro75xxy5j
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
1t5tq
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am